Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep-Oct;41(5):363-368.
doi: 10.1097/NOR.0000000000000883.

Chronic Heart Failure: A Pharmacologic Review

Shereen Salama  1   2   3 , Aeman Choudhury  1   2   3 , Sean P Kane  1   2   3
Affiliations
Review

Chronic Heart Failure: A Pharmacologic Review

Shereen Salama et al. Orthop Nurs. 2022 Sep-Oct.

Abstract

Chronic heart failure affects over 6 million Americans and is the main reason that people older than 65 years get admitted to the hospital (Centers for Disease Control and Prevention, 2020). Management of heart failure requires interdisciplinary efforts involving primary care physicians, cardiologists, nurses, and pharmacists among other providers. Nurses can play a key role in identifying patients at risk for heart failure exacerbation and are often at the front lines providing education regarding medication adherence. This article summarizes the medications used in chronic heart failure and describes common side effects, dosing considerations, and counseling points that are essential for appropriate management.

PubMed Disclaimer

References

    1. Anker S. D., Butler J., Filippatos G., Ferreira J. P., Bocchi E., Böhm M., Brunner-La Rocca H. P., Choi D. J., Chopra V., Chuquiure-Valenzuela E., Giannetti N., Gomez-Mesa J. E., Janssens S., Januzzi J. L., Gonzalez-Juanatey J. R., Merkely B., Nicholls S. J., Perrone S. V., Piña I. L., Packer M.; EMPEROR-Preserved Trial Investigators. (2021). Empagliflozin in heart failure with a preserved ejection fraction. The New England Journal of Medicine, 385(16), 1451–1461. https://doi.org/10.1056/NEJMoa2107038 - DOI
    1. Armstrong P. W., Pieske B., Anstrom K. J., Ezekowitz J., Hernandez A. F., Butler J., Lam C. S. P., Ponikowski P., Voors A. A., Jia G., McNulty S. E., Patel M. J., Roessig L., Koglin J., O'Connor C. M.; VICTORIA Study Group. (2020). Vericiguat in patients with heart failure and reduced ejection fraction. The New England Journal of Medicine, 382(20), 1883–1893. https://doi.org/10.1056/NEJMoa1915928 - DOI
    1. Benjamin E. J., Muntner P., Alonso A., Bittencourt M. S., Callaway C. W., Carson A. P., Chamberlain A. M., Chang A. R., Cheng S., Das S. R., Delling F. N., Djousse L., Elkind M. S. V., Ferguson J. F., Fornage M., Jordan L. C., Khan S. S., Kissela B. M., Knutson K. L., Virani S. S. (2019). Heart disease and stroke statistics—2019 update: A report from the American Heart Association external icon. Circulation. 139(10), e56–528.
    1. Centers for Disease Control and Prevention. (2020). Heart Disease Resources for Health Care Professionals. https://www.cdc.gov/heartdisease/heart_failure.htm
    1. Francis G. S. (2001). Pathophysiology of chronic heart failure. The American Journal of Medicine, 110 (Suppl. 7A), 37S–46S. https://doi.org/10.1016/s0002-9343(98)00385-4 - DOI